Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label eculizumab study in adults with atypical hemolytic-uremic syndrome
ACTRN12611000498998Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Proportion of patients with complete TMA response. Started Jul 2011; status: terminated.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on ACTRN12611000498998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000498998.